Table 1 Clinical trials of therapeutic vaccines in lung cancer

MAGE-A3

II

182

IB/II

DFI: (HR: 0.75, 95 % CI, 0.46 to 1.23; two-sided P = .254); DFS: (HR: 0.76; 95 % CI, 0.48 to 1.21; P = .248); OS: (HR, 0.81; 95 % CI, 0.47 to 1.40; P = .454) [59].

BLP25

II

171

IIIB/IV

Median OS: 17.4 months with L-BLP25/BSC vs 13.0 months with BSC alone [68].

Subset analysis (n = 65):

Median OS: 30.6 months with L-BLP25/BSC vs 13.3 months with BSC alone [69].

III

1239

III

Median OS: 25.6 months with L-BLP25 vs 22.3 months with placebo [70].

Subset analysis (patients with previous chemoradiotherapy):

Median OS: 30.8 months with L-BLP25 vs 20.6 months with placebo [70].

Belagenpumatucel-L

II

75

II/IV

Estimated 2-years survival: 52 % with high doses vs 20 % with low doses [75].

III

532

III/IV

Median OS: 20.3 months with belagenpumatucel-L vs 17.8 months with placebo [76].

Subset analysis (patients with pretreatment radiation):

Median OS: 40.1 months with belagenpumatucel-L vs 10.3 months with placebo [76].

CIMAvax EGF

II

80

IIIB/IV

Median survival: 11.7 months with GAR vs 3.6 months with PAR [81].

TG4010

II

148

IIIB/IV

6-months PFS: 43.2 % with TG4010/chemotherapy vs 35.1 % with chemotherapy alone [84].